Home
About
Overview
Sharing Data
ORCID
Help
History (12)
In Reply: A Comparison of Minimally Invasive and Open Transforaminal Lumbar Interbody Fusion for Grade 1 Degenerative Lumbar Spondylolisthesis: An Analysis of the Prospective Quality Outcomes Database.
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
The application of precision medicine in diagnosing familial Mediterranean fever.
Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective.
Making the Case for Accelerated Withdrawal of Aducanumab.
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Making the Case for Accelerated Withdrawal of Aducanumab.
Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.
View in:
PubMed
subject areas
Alzheimer Disease
Antibodies, Monoclonal, Humanized
Drug Approval
Humans
United States
United States Food and Drug Administration
authors with profiles
George Perry